Celyad Oncology Sa Quick Ratio (CYAD) starting from the second quarter 2023 to second quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Celyad Oncology Sa  (NASDAQ: CYAD)

Celyad Oncology Sa's Quick Ratio

CYAD's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2023, Quick Ratio deteriorated to 0.82 a new company low.

Within Major Pharmaceutical Preparations industry 503 other companies have achieved higher Quick Ratio than Celyad Oncology Sa in second quarter 2023. While Quick Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 2019 to 3014.

Explain Quick Ratio?
How much Cash & cash equivalents CYAD´s has?
What are CYAD´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CYAD Quick Ratio (Jun 30 2023)
Q4		 (Dec 31 2022)
Q3		 0
Q2		 0
Q1		 0
Q4
Y / Y Current Liabilities Change -43.03 % -24.6 % -24.6 % -24.6 % -24.6 %
Y / Y Cash & cash equivalent Change -61.02 % -58.54 % -58.54 % -55.21 % -58.54 %
Quick Ratio MRQ 0.82 1.19 1.19 1.29 1.19
CYAD's Total Ranking # 3014 # 2019 # 2021 # 2016 #
Seq. Current Liabilities Change -43.03 % 0 % 0 % 0 % -24.6 %
Seq. Cash & cash equivalent Change -61.02 % 0 % -7.45 % 8.04 % -58.54 %



Quick Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 504
Healthcare Sector # 943
Overall Market # 3014


Quick Ratio Statistics
High Average Low
4.29 2.48 0.82
(Dec 31 2016)   (Jun 30 2023)




Financial Statements
Celyad Oncology Sa's Current Liabilities $ 7 Millions Visit CYAD's Balance sheet
Celyad Oncology Sa's Cash & cash equivalent $ 5 Millions Visit CYAD's Balance sheet
Source of CYAD's Sales Visit CYAD's Sales by Geography


Cumulative Celyad Oncology Sa's Quick Ratio

CYAD's Quick Ratio for the trailling 12 Months

CYAD Quick Ratio

 (Jun 30 2023)
12 Months		 (Dec 31 2022)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months
Y / Y Current Liabilities TTM Growth -28.3 % -24.6 % -15.4 % -5.49 % 5.23 %
Y / Y Cash & cash equivalent TTM Growth -57.87 % -57.71 % -36.29 % -9.08 % 25.43 %
Quick Ratio TTM 1.16 1.22 1.52 1.77 1.97
Total Ranking TTM # 4947 # 4717 # 4724 # 4673 #
Seq. Current Liabilities TTM Growth -10.76 % -7.54 % -7.01 % -6.55 % -6.15 %
Seq. Cash & cash equivalent TTM Growth -14.95 % -25.71 % -20.45 % -16.17 % -14.64 %

Quick ratio ranking by company, industry and sector >> Back to CYAD Financial Strength Comparisons >> Go to Compare CYAD Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in CYAD's Current Liabilities to $6.65 millions, cumulative Quick Ratio to 1.16 below the CYAD average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 608 other companies have achieved higher Quick Ratio than Celyad Oncology Sa. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2022 from 4717 to 4947.

Explain Quick Ratio?
How much Cash & cash equivalents CYAD´s has?
What are CYAD´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 609
Healthcare Sector # 1227
Within the Market # 4947


trailing twelve months Quick Ratio Statistics
High Average Low
4.2 2.46 1.19
(Dec 31 2018)   (Dec 31 2022)




Companies with similar Quick Ratio in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2023 MRQ Cash & cash equivalentJun 30 2023 MRQ Current Liabilities
Curevac N v   2.19 $ 456.571  Millions$ 208.756  Millions
Bellicum Pharmaceuticals Inc   2.13 $ 7.410  Millions$ 3.482  Millions
Longeveron Inc   2.12 $ 8.657  Millions$ 4.082  Millions
Actinium Pharmaceuticals Inc  2.09 $ 91.276  Millions$ 43.637  Millions
Liminal Biosciences Inc   2.09 $ 14.595  Millions$ 6.982  Millions
Ocular Therapeutix Inc   2.06 $ 66.606  Millions$ 32.357  Millions
Royalty Pharma Plc  2.06 $ 2,178.177  Millions$ 1,059.341  Millions
Neurosense Therapeutics Ltd  2.05 $ 7.089  Millions$ 3.459  Millions
Pacira Biosciences inc   2.03 $ 220.766  Millions$ 108.912  Millions
Oculis Holding Ag  2.01 $ 45.600  Millions$ 22.710  Millions
Acadia Pharmaceuticals Inc   2.00 $ 375.378  Millions$ 187.942  Millions
Tg Therapeutics Inc   1.99 $ 144.905  Millions$ 72.667  Millions
Hutchmed china Limited  1.99 $ 857.373  Millions$ 431.723  Millions
Biomarin Pharmaceutical Inc  1.96 $ 1,170.958  Millions$ 597.231  Millions
Equillium Inc   1.95 $ 48.378  Millions$ 24.802  Millions
Apollomics Inc   1.87 $ 25.296  Millions$ 13.556  Millions
Grace Therapeutics Inc  1.83 $ 5.428  Millions$ 2.960  Millions
Adlai Nortye Ltd  1.82 $ 91.492  Millions$ 50.317  Millions
Endo International Plc  1.82 $ 1,025.625  Millions$ 564.882  Millions
Galectin Therapeutics Inc   1.81 $ 17.966  Millions$ 9.953  Millions
Nucana Plc  1.76 $ 22.348  Millions$ 12.676  Millions
Talphera Inc   1.76 $ 7.410  Millions$ 4.220  Millions
Cyclerion Therapeutics Inc   1.75 $ 5.641  Millions$ 3.217  Millions
Casi Pharmaceuticals inc   1.74 $ 29.094  Millions$ 16.726  Millions
Kyntra Bio Inc   1.73 $ 335.716  Millions$ 194.072  Millions
Mersana Therapeutics inc   1.72 $ 128.732  Millions$ 74.920  Millions
Alkermes Plc   1.70 $ 829.049  Millions$ 487.185  Millions
Aslan Pharmaceuticals Limited  1.67 $ 40.944  Millions$ 24.477  Millions
Amicus Therapeutics inc   1.67 $ 265.626  Millions$ 159.235  Millions
Quantum Cyber N v   1.67 $ 17.982  Millions$ 10.797  Millions

Date modified: 2026-06-22T17:07:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.